Physician profile
Andrew Pham
NPI 1841646171
$3,540.37
in general payments reported to CMS, 2019-2025
23 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $183 · 2021: $896 · 2022: $519 · 2023: $561 · 2024: $419 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.08 | 2019-2022 | |
| Abbvie INC. | $471.62 | 2021-2023 | |
| Amgen INC. | $426.96 | 2019-2021 | |
| Lilly USA, LLC | $369.34 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $348.78 | 2021-2024 | Breztri |
| Glaxosmithkline, LLC. | $212.11 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $183.28 | 2022-2025 | Proclaim |
| Gilead Sciences, INC. | $173.67 | 2020-2023 | Epclusa |
| Bard Peripheral Vascular, INC. | $154.43 | 2025 | |
| Merck Sharp & Dohme LLC | $131.14 | 2020-2024 | Gardasil 9, Gardasil, Vaxelis |
| Dexcom, INC. | $123.75 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $58.70 | 2021 | |
| Intuitive Surgical, INC. | $50.00 | 2023 | Da Vinci Surgical System |
| Pfizer INC. | $39.30 | 2022-2025 | |
| Exact Sciences Corporation | $37.94 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2021-2024 | Jardiance |
| Cipher Pharmaceuticals US LLC | $27.57 | 2025 | Natroba, Spinosad |
| Alk-Abello, INC | $25.45 | 2023 | Ragwitek, Grastek, Odactra |
| Biogen, INC. | $21.64 | 2025 | Zurzuvae |
| Eisai INC. | $19.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.47 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.36 | 2024 | Euflexxa |
| Providence Medical Technology, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.